VALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA.
2/5 보강
OpenAlex 토픽 ·
Thyroid Cancer Diagnosis and Treatment
Thyroid and Parathyroid Surgery
Thyroid Disorders and Treatments
[CONTEXT] The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world sett
- p-value p = 0.003
- p-value p = 0.012
APA
Claudia Moneta, Matteo Trevisan, et al. (2026). VALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA.. The Journal of clinical endocrinology and metabolism. https://doi.org/10.1210/clinem/dgag167
MLA
Claudia Moneta, et al.. "VALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA.." The Journal of clinical endocrinology and metabolism, 2026.
PMID
41994857 ↗
Abstract 한글 요약
[CONTEXT] The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world setting.
[DESIGN] Retrospective observational study.
[SETTING] Tertiary care center.
[PATIENTS] Data from 670 PTC patients with complete histopathological and final disease outcome were included.
[MAIN OUTCOME MEASURES] We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction.
[RESULTS] The reclassification according to the 2025 ATA risk stratification showed that the proportion of "low-risk" PTC decreased by 22.2%, while "intermediate-risk" and "high-risk" PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the two stratification systems revealed that structural disease persistence in the 2025 "low-risk" and "high-risk" classes was comparable. The 2025 "intermediate-high-risk" class was similar to the former "intermediate-risk" class, whereas the "low-intermediate-risk" class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 "low-risk" class (p = 0.003), but lower than that of the 2015 "intermediate-risk" class (p = 0.012).
[CONCLUSIONS] In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined "low-intermediate-risk" class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior "low-risk" and "intermediate-risk" classes, highlighting the need for dedicated prospective studies to address proper management of this newly-defined group of patients.
[DESIGN] Retrospective observational study.
[SETTING] Tertiary care center.
[PATIENTS] Data from 670 PTC patients with complete histopathological and final disease outcome were included.
[MAIN OUTCOME MEASURES] We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction.
[RESULTS] The reclassification according to the 2025 ATA risk stratification showed that the proportion of "low-risk" PTC decreased by 22.2%, while "intermediate-risk" and "high-risk" PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the two stratification systems revealed that structural disease persistence in the 2025 "low-risk" and "high-risk" classes was comparable. The 2025 "intermediate-high-risk" class was similar to the former "intermediate-risk" class, whereas the "low-intermediate-risk" class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 "low-risk" class (p = 0.003), but lower than that of the 2015 "intermediate-risk" class (p = 0.012).
[CONCLUSIONS] In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined "low-intermediate-risk" class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior "low-risk" and "intermediate-risk" classes, highlighting the need for dedicated prospective studies to address proper management of this newly-defined group of patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The Role of Probiotics , , and in Inhibziting Pathogens, Maintaining Gut Health, and Improving Disease Outcomes.
- Long-Term Clinical Consequences of Severe Oral Mucositis in Survivors of Lip, Oral Cavity, and Pharynx Cancer Versus Leukemia: A Propensity-Score-Matched Comparative Cohort Study Using Real-World Data.
- Associations between preoperative thyroid parameters, aggressive clinicopathological features and risk of recurrence in differentiated thyroid cancer.
- Hemithyroidectomy versus total thyroidectomy for patients with differentiated thyroid cancer: a systematic review and meta-analysis.
- What Has Changed in the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer? Part 2: Postoperative Initial Treatment.
- Comparative Study of Two Successive American Thyroid Association Risk Stratification Systems in Patients with Differentiated Thyroid Cancer in India.